Sift Biosciences closes an oversubscribed $3.7M Pre-Seed round led by Freeflow Ventures and Lifespan Vision Ventures to advance its T-cell immunotherapy platform.
Amount Raised
$3.7 Million
Round Type
Pre-Seed
CaliforniaBiotechnologyHealth CareTherapeuticsInvestors
Description
Sift Biosciences has secured $3.7M in Pre-Seed financing to develop next-generation peptide immunotherapies. The funding was co-led by Freeflow Ventures and Lifespan Vision Ventures, with other participants. This financing will help demonstrate proof-of-concept for their innovative platform. The aim is to address treatment gaps in immunologically 'cold' solid tumors.
Quick answer
Sift Biosciences raised $3.7 Million in a Pre-Seed round, dated February 18, 2026. Investors: Valuence Ventures, Eisai Innovation, SBI US Gateway Fund, Freeflow Ventures and Lifespan Vision Ventures. Sift Biosciences is based in California, United States.
- How much did Sift Biosciences raise?
- Sift Biosciences raised $3.7 Million in a Pre-Seed round on February 18, 2026.
- Who invested in Sift Biosciences?
- Valuence Ventures, Eisai Innovation, SBI US Gateway Fund, Freeflow Ventures and Lifespan Vision Ventures are named as investors in this round.
- What does Sift Biosciences do?
- Sift Biosciences is a preclinical immunotherapy company developing “T-cell booster” peptides designed to amplify immune responses in cancers and other immune diseases where current therapies fail.
- Where is Sift Biosciences based and how big is it?
- Sift Biosciences is based in California, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Sift Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Sonire Therapeutics raised $18M (Series A) on March 31, 2026.
- TippingPoint Biosciences raised $4.5M (Seed) on March 31, 2026.
- Denali Therapeutics raised $200M (Debt Financing) on March 31, 2026.
- Oncomatryx Biopharma raised $67M (Corporate Round) on March 30, 2026.
- Marvel Biosciences raised $476K (Grant) on March 30, 2026.
- Cellbricks Therapeutics raised $8.1M (Seed) on March 26, 2026.
Who to call at Sift Biosciences, and when
A new round usually means Sift Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sift Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sift Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sift Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sift Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Sift Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.